Overview and definition
Diffuse-type tenosynovial giant cell tumor (D-TGCT) is a benign but locally aggressive neoplasm arising from the synovial lining of joints, bursae, and tendon sheaths.[1][2] In the maxillofacial region, the temporomandibular joint (TMJ) is the site of involvement, where the tumor characteristically produces an ill-defined, infiltrative mass with extensive bone erosion and frequent skull base extension.[3][4] The underlying pathogenesis involves chromosomal rearrangements—most commonly t(1;2)(p13;q37)—that fuse the CSF1 gene with COL6A3 or other partners, driving overexpression of colony-stimulating factor 1 (CSF1) and recruitment of non-neoplastic macrophages, giant cells, and inflammatory cells in a "landscape effect".[2][5] On imaging, the hallmark is a soft tissue mass with hemosiderin-related signal characteristics; management centers on complete surgical resection.
Terminology and classification
Current Classification
The WHO Classification of Soft Tissue and Bone Tumours unifies these lesions under the term tenosynovial giant cell tumor (TGCT), with two recognized subtypes: localized and diffuse.[1][2] The diffuse type corresponds to the entity historically known as pigmented villonodular synovitis (PVNS) when intra-articular, and diffuse-type giant cell tumor of tendon sheath when extra-articular.[6][7]
Obsolete and Alias Terms
- Pigmented villonodular synovitis (PVNS)—still widely used in clinical practice and older literature
- Diffuse-type giant cell tumor (Dt-GCT)
- Pigmented villonodular tenosynovitis (PVNTS)—used for extra-articular diffuse disease
- Villonodular synovitis
- Xanthogranuloma, benign synovioma, fibrous xanthoma of the synovium—historical terms that should be avoided[8]
The abbreviation D-TGCT is preferred in current literature.[1][2]
Epidemiology
D-TGCT is classified as an orphan disease. Nationwide registry studies report an incidence of approximately 4–8 per million person-years for the diffuse subtype.[9][10] There is a slight female predominance, and peak incidence occurs between ages 30 and 50, though the tumor can arise at any age.[2][10]
The knee is the most commonly affected joint overall, followed by the hip and ankle.[2][6] TMJ involvement is rare; the largest single-institution series reported 22 cases over a 9-year period.[3] A systematic review identified approximately 115 reported TMJ cases in the literature.[3] Within the TMJ, D-TGCT shows a notable predilection for the chondroid variant (chondroid metaplasia), which is disproportionately common compared to other anatomic sites.[4][11]
Clinical presentation
Presentation and Symptoms
TMJ D-TGCT typically presents as a slowly progressive, unilateral preauricular mass.[3][4] The most common symptoms include:
- Pain (headache, otalgia, or TMJ pain)
- Hearing loss (conductive, from temporal bone erosion or external auditory canal involvement)
- Preauricular or temporal swelling
- Limited mouth opening or TMJ dysfunction
- Facial nerve weakness (rare)
Tempo and Diagnostic Delay
The clinical course is indolent, and symptoms are nonspecific. The median delay from symptom onset to diagnosis is approximately 24 months.[4] Initial misdiagnosis as a parotid tumor, degenerative joint disease, or other TMJ pathology is common.[12][13]
Complications
Locally aggressive growth leads to erosion of the mandibular condyle, glenoid fossa, temporal bone, and zygomatic arch. Skull base destruction with intracranial extension into the middle cranial fossa occurs in a substantial proportion of TMJ cases.[3][14][15] Erosion into the external auditory canal and epitympanic space may produce conductive hearing loss.[15] Despite aggressive local behavior, distant metastasis is exceedingly rare.[3][7]
Radiographic findings
Location and Distribution
D-TGCT of the TMJ presents as a mass centered on or adjacent to the temporomandibular joint. Wang et al. classified the radiologic presentation into three types:[11]
- Bone-centered type: lobulated, expansile mass with incomplete bony shell and soft tissue extension—the most common pattern
- Intraosseous type: expansile growth with a complete bony shell and no soft tissue extension
- Soft tissue type: predominant soft tissue nodules with speckled high-density ossification and secondary extension into the mandibular condyle; this type may involve the parotid gland
Periphery and Shape
The mass is characteristically ill-defined and infiltrative, lacking a well-demarcated capsule.[1][7] In less aggressive presentations, the lesion may appear lobulated and expansile with partial cortical preservation.[11][16]
Internal Architecture
- On CT, the solid component demonstrates higher attenuation than adjacent soft tissue, reflecting hemosiderin content and cellularity. Mixed-density areas correspond to cystic or necrotic regions within larger tumors.[12][17][18]
- On panoramic radiographs or conventional radiography, findings are nonspecific and may include a poorly defined radiolucency or erosive change at the condyle and glenoid fossa. Plain films are insensitive and frequently appear normal or show only subtle condylar irregularity.
- On CBCT, osseous erosion of the condyle, glenoid fossa, and adjacent temporal bone is better delineated than on panoramic imaging. Cortical disruption, condylar expansion or destruction, and extension into the middle cranial fossa floor may be identified, though the soft tissue component is poorly characterized without contrast enhancement.
Effects on Adjacent Structures
- Condylar erosion or destruction is common, ranging from scalloping to complete loss of the condylar head[4][16][19]
- Erosion of the glenoid fossa, squamous temporal bone, and zygomatic arch is characteristic of advanced disease[15][16]
- Extension into the infratemporal fossa and masticator space along the lateral pterygoid muscle is frequently observed[16]
- Skull base destruction with penetration into the middle cranial fossa occurs in a substantial minority of TMJ cases[3][19]
- Erosion into the external auditory canal and epitympanic space is occasional[15]
Growth Pattern and Extent
The tumor grows in an infiltrative, locally aggressive fashion, often involving a large volume of tissue by the time of diagnosis. Lesions reported in TMJ series commonly measure 4–6 cm at presentation.[18][20] The growth pattern follows synovial-lined spaces and extends along fascial planes into the masticator space, parotid region, and skull base.[3][16]
Recognized Variants
The chondroid variant (chondroid metaplasia) is disproportionately common in TMJ D-TGCT compared to other sites, identified in the majority of TMJ cases in one series.[4][11] This variant may produce areas of speckled calcification or ossification within the mass, potentially mimicking synovial chondromatosis or chondrosarcoma on imaging.[11][21]
Other imaging findings
MRI Signal Characteristics
MRI is the reference standard for characterizing D-TGCT and defining its extent.[22][23] The signature finding is diffuse low signal intensity on both T1- and T2-weighted sequences, reflecting abundant hemosiderin deposition within the tumor.[16][22][23] On gradient-echo sequences, a pronounced "blooming" artifact from paramagnetic hemosiderin is considered nearly pathognomonic.[22][24] Enhancement after gadolinium administration is variable.[4][16]
In larger tumors, cystic or necrotic areas may show high T2 signal, creating a mixed-signal mass; however, the solid component retains characteristic hypointensity.[17][18]
CT (Medical)
Contrast-enhanced CT demonstrates a soft tissue density mass with higher attenuation than muscle, often with avid enhancement.[16][18] CT is superior to MRI for delineating the extent of osseous destruction, including cortical breakthrough at the skull base, temporal bone, and zygomatic arch.[16] CT and MRI are complementary for surgical planning.
PET/CT
FDG PET/CT may show markedly increased uptake in the solid component (SUVmax reported up to 19.8 in one TMJ case), which can raise concern for malignancy.[18] PET/CT is not routinely indicated but may be encountered during workup of an unknown skull base mass.
Differential diagnosis
The differential diagnosis of a destructive mass centered on the TMJ with bone erosion and soft tissue extension includes several entities. The hemosiderin-related low T2 signal and blooming artifact on MRI are the most reliable discriminators for D-TGCT.
| Entity | Why it is considered | Best discriminator |
|---|---|---|
| Synovial chondromatosis | TMJ mass with calcified loose bodies and joint space expansion | Characteristic ring-and-arc calcifications and absence of hemosiderin-related low T2 signal distinguish SC; SC typically lacks aggressive bone destruction[16][25] |
| Chondrosarcoma | Destructive TMJ mass with chondroid matrix calcification | Lesion centered on condyle with periosteal reaction, infiltrative enhancement, and absent hemosiderin blooming favors chondrosarcoma[26] |
| Giant cell tumor of bone | Lytic, expansile lesion of the condyle or temporal bone | GCT shows intermediate-to-low T2 signal but lacks the diffuse hemosiderin deposition and blooming artifact characteristic of D-TGCT; GCT of the craniofacial skeleton is exceedingly rare[16][27] |
| Synovial sarcoma | Expansile lytic mass with condylar and ramus destruction | T2 hyperintensity, solid enhancement, and absence of hemosiderin blooming distinguish synovial sarcoma; SS18::SSX fusion is confirmatory[16][28] |
The highest-risk diagnostic pitfall is misidentification of the chondroid variant of D-TGCT as chondroblastoma or chondrosarcoma, given the frequency of chondroid metaplasia in TMJ lesions.[4][16] Biopsy with radiologic-pathologic correlation is essential when imaging is equivocal; the combination of hemosiderin-laden stroma and giant cells on histology, together with low T2 signal and blooming on MRI, confirms the diagnosis.
Histopathology
Microscopic Findings
The diagnostic histologic pattern consists of:[1][6][16]
- Villous and nodular synovial hyperplasia with thickened intimal lining
- Mononuclear histiocyte-like cells—the predominant cell population, including small round cells and larger epithelioid cells with abundant eosinophilic cytoplasm and eccentric nuclei
- Multinucleated osteoclast-like giant cells—variable in number
- Hemosiderin deposition—both intracellular (siderophages) and extracellular, often prominent
- Foamy macrophages (xanthoma cells)
- Lymphocytic infiltrate with occasional plasma cells
- Fibrous stroma with variable collagenization
Mitotic activity may be brisk in stromal cells but is not indicative of malignancy when present in isolation.[7][29]
Chondroid Variant
Chondroid metaplasia is characteristic of TMJ D-TGCT, identified in the majority of cases in several series.[4][11] Areas of chondroid matrix may mimic chondroblastoma or synovial chondromatosis, necessitating careful clinicopathologic correlation.[16][21]
Immunohistochemistry and Molecular Findings
- Mononuclear cells and giant cells are positive for CD68; desmin-positive dendritic cells with paranuclear inclusions may be present[7][16]
- CSF1 rearrangements—most commonly t(1;2)(p13;q37) fusing CSF1 with COL6A3—are identified in a subset of cases; other fusion partners (VCAM1, FN1, CDH1) and CSF1 exon 9 deletions account for additional cases[5][28][30]
- Molecular analysis is generally not required for diagnosis but may be confirmatory in difficult cases[1]
Malignant Transformation
Malignant transformation is exceedingly rare, characterized by cytologic atypia, necrosis, and brisk atypical mitoses within an otherwise typical D-TGCT.[7][31] Sarcomatous change may produce metastatic disease.
Management and prognosis
Workup and Referral
When a destructive TMJ mass is identified, MRI with gradient-echo sequences and contrast-enhanced CT should be obtained to characterize the lesion and define its extent.[16][22] Biopsy (core needle or incisional) is required for definitive diagnosis before surgical planning.[4][21] Referral to a multidisciplinary team including oral and maxillofacial surgery, head and neck surgery, and neurosurgery (when skull base involvement is present) is appropriate.
Surgical Treatment
Complete surgical resection is the primary treatment and offers the best chance of long-term cure.[3][4][14]